Peest D, Deicher H, Coldewey R, Schmoll H J, Schedel I
Abteilung Immunologie und Transfusionsmedizin, Medizinische Hochschule Hannover, F.R.G.
Eur J Cancer Clin Oncol. 1988 Jun;24(6):1061-7. doi: 10.1016/0277-5379(88)90160-5.
In a prospective multicenter trial, 320 untreated myeloma patients of stage II and III were randomized for remission induction into two groups receiving six monthly courses of either MP or VCMP treatment. Response rates were equal in both groups: 72% remission, 21% no change, 7% progress for patients evaluable by TCM changes and 56% remission, 11% no change, 33% progress for BJ- and non-secretory myelomas. The overall survival rate was 60% after 4 years. An unexpected finding was the significantly longer survival of MP treated patients compared to the VCMP group. After successful remission induction, patients were randomized into one group receiving maintenance treatment using the induction scheme q 8 weeks, and another group without further chemotherapy. Although patients in the latter group relapsed significantly earlier, differences between both groups concerning acquired resistance to first line therapy or survival have not been noticed to date.
在一项前瞻性多中心试验中，320例未经治疗的II期和III期骨髓瘤患者被随机分组进行缓解诱导治疗，分为两组，分别接受为期6个月的MP或VCMP治疗。两组的缓解率相当：可通过中医改变评估的患者中，72%缓解，21%无变化，7%进展；BJ型和非分泌型骨髓瘤患者中，56%缓解，11%无变化，33%进展。4年后的总生存率为60%。一个意外发现是，与VCMP组相比，接受MP治疗的患者生存期显著更长。成功诱导缓解后，患者被随机分为一组，采用诱导方案每8周接受一次维持治疗，另一组不进行进一步化疗。尽管后一组患者复发明显更早，但迄今为止，两组在对一线治疗的获得性耐药或生存期方面的差异尚未被发现。
